Skip to content

Author

E. Ferrari

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Aug 2026

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.

BACKGROUND Many stable patients with chronic coronary syndrome continue β-blocker therapy for years after a myocardial infarction, despite having no clear ongoing indication. Whether β-blockers can be safely discontinued in such patients remains uncertain. The objective of this analysis was to assess the non-inferiorit...

J. Silvain, K. Choi, Victorien Monguillon et al. · 1 citation
Open access Aug 2026

LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.

In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year.

G. Montalescot, E. Ferrari, G. Souteyrand et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.